Cargando…
Caspase-2 is a mediator of apoptotic signaling in response to gemtuzumab ozogamicin in acute myeloid leukemia
The antibody conjugate gemtuzumab ozogamicin (GO; Mylotarg(®)) provides targeted therapy of acute myeloid leukemia (AML), with recent approvals for patients with CD33-positive disease at diagnosis or relapse, as monotherapy or combined with chemotherapeutics. While its clinical efficacy is well docu...
Autores principales: | Hååg, Petra, Olsson, Magnus, Forsberg, Jeremy, Lindberg, Marita Lagergren, Stenerlöw, Bo, Zong, Dali, Kanter, Lena, Lewensohn, Rolf, Viktorsson, Kristina, Zhivotovsky, Boris, Stenke, Leif |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9188552/ https://www.ncbi.nlm.nih.gov/pubmed/35690610 http://dx.doi.org/10.1038/s41420-022-01071-9 |
Ejemplares similares
-
Gemtuzumab Ozogamicin: Back Again
por: Selby, Chris, et al.
Publicado: (2019) -
Gemtuzumab ozogamicin: Various toxicities: 2 case reports
Publicado: (2017) -
Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin
por: Gottardi, Michele, et al.
Publicado: (2021) -
Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment
por: Fenwarth, Laurène, et al.
Publicado: (2020) -
Pharmacokinetic/Pharmacodynamic Modeling to Support the Re‐approval of Gemtuzumab Ozogamicin
por: Fostvedt, Luke K., et al.
Publicado: (2019)